<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584376</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT00584376</nct_id>
  </id_info>
  <brief_title>Pregabalin (Lyrica) for the Treatment of Essential Tremor</brief_title>
  <official_title>A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-site, prospective, double-blind, randomized, placebo-controlled,&#xD;
      crossover trial conducted over 6 months to assess the effectiveness and safety of PGB to&#xD;
      treat symptoms of ET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fahn-Tolosa-Marin Essential Tremor Rating Scale (FTM) total score</measure>
    <time_frame>61 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Writing tablet recordings of tremor amplitude</measure>
    <time_frame>61 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Gradually titrated dose ranging from 75mg po bid to 225mg po bid.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients with essential tremor diagnosed by a movement disorder specialist.&#xD;
&#xD;
          2. Age 18 years to 80 years.&#xD;
&#xD;
          3. Postural tremor severity score of greater than or equal to 2 in the dominant hand/arm&#xD;
             as measured by the FTM rating scale.&#xD;
&#xD;
          4. Women of child-bearing potential must use a reliable method of contraception and must&#xD;
             provide a negative pregnancy test at entry into the study.&#xD;
&#xD;
          5. Baseline EKG read as within normal limits (no clinically significant&#xD;
             abnormalities)obtained from primary care physician or cardiologist (performed within&#xD;
             the past year).&#xD;
&#xD;
          6. Serum creatine kinase, complete metabolic blood count, liver function tests, renal&#xD;
             function tests, and platelets are within normal limits (blood drawn within the past&#xD;
             year).&#xD;
&#xD;
          7. Stable doses of all medications for 30 days prior to study entry and for the duration&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any illness that in the investigator's opinion preclude participation in this study.&#xD;
&#xD;
          2. Pregnancy or lactation.&#xD;
&#xD;
          3. Concurrent participation in another clinical study.&#xD;
&#xD;
          4. Dementia or other psychiatric illness that prevents the patient from giving informed&#xD;
             consent (Mini Mental Status Exam score less than 24).&#xD;
&#xD;
          5. Legal incapacity or limited legal capacity.&#xD;
&#xD;
          6. Presence of severe renal disease (BUN 50% greater than normal or creatine clearance&#xD;
             &lt;60 mL/min) or hepatic disease.&#xD;
&#xD;
          7. Presence of severe daytime sleepiness.&#xD;
&#xD;
          8. Abnormal creatine kinase and/or platelet count in the past year.&#xD;
&#xD;
          9. Present complaints of somnolence, dizziness, blurred vision, bleeding tendencies,&#xD;
             cardiac abnormalities.&#xD;
&#xD;
         10. Previous lack of response to other ET therapies (propranolol AND primidone).&#xD;
&#xD;
         11. Patients who have had deep brain stimulation (DBS).&#xD;
&#xD;
         12. Concomitant treatment with gabapentin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa A Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ. School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois U. School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Theresa Zesiewicz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Essential tremor</keyword>
  <keyword>tremor</keyword>
  <keyword>pregabalin</keyword>
  <keyword>lyrica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 6, 2018</submitted>
    <returned>May 1, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

